Akston, the Biotech Built for Pets, today announced results from a randomized head-to-head study evaluating AKS-548d and AKS-734, the company's NGF-targeting Ambifect® Fc-fusion immunotherapeutic ...
Bárbara Miragaia of MFA Legal & Tech argues that the regime’s restrictive eligibility rules and limited relief for ...
An analysis of the June 2026 final rulemaking that updated the federal independent dispute resolution (IDR) process, the binding mechanism established under the No Suprises Act (NSA) to resolve out-of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results